论文部分内容阅读
目的:探讨E-cadherin、β-catenin及Cyclin D1在肾透明细胞癌(RCCC)中的表达及意义。方法:用免疫组化法检测E-cadherin、β-catenin及Cyclin D1在67例RCCC组织中的表达情况,并分析其与预后的关系。结果:E-cadherin及Cyclin D1在RCCC组织中表达率分别为35.8%(24/67)和44.8%(30/67)。β-catenin在RCCC组织中胞膜和胞质表达率分别为23.9%(16/67)和68.7%(46/67)。E-cadherin在RCCC组织中的表达与肿瘤病理分级及临床分期相关(r=0.393,P=0.001;r=0.365,P=0.002)。E-cadherin与β-catenin胞膜表达之间具有显著相关性,r=0.531,P=0.000。β-catenin在RC-CC组织中胞膜表达与肿瘤临床分期相关,r=0.386,P=0.001。Cyclin D1与β-catenin胞膜表达之间具有显著相关性,r=0.481,P=0.000。Cyclin D1在RCCC中的表达与肿瘤体积大小具有相关性,r=0.325,P=0.007。结论:E-cadherin和β-catenin蛋白低表达或异常表达与RCCC的病理分级和临床分期有关,并对RCCC预后评价有一定参考意义。
Objective: To investigate the expression and significance of E-cadherin, β-catenin and Cyclin D1 in renal clear cell carcinoma (RCCC). Methods: The expressions of E-cadherin, β-catenin and Cyclin D1 in 67 cases of RCCC tissues were detected by immunohistochemistry, and their relationship with prognosis was analyzed. Results: The expression rates of E-cadherin and Cyclin D1 in RCCC tissues were 35.8% (24/67) and 44.8% (30/67), respectively. The expression of β-catenin in the RCCC tissues was 23.9% (16/67) and 68.7% (46/67), respectively. The expression of E-cadherin in RCCC tissues correlated with tumor pathological grade and clinical stage (r = 0.393, P = 0.001; r = 0.365, P = 0.002). There was a significant correlation between E-cadherin and β-catenin cell membrane expression, r = 0.531, P = 0.000. The membrane expression of β-catenin in RC-CC tissues correlated with the clinical stage of the tumor, r = 0.386, P = 0.001. There was a significant correlation between Cyclin D1 and β-catenin cell membrane expression, r = 0.481, P = 0.000. The expression of Cyclin D1 in RCCC was correlated with tumor volume, r = 0.325, P = 0.007. Conclusion: The low expression or abnormal expression of E-cadherin and β-catenin is related to the pathological grade and clinical stage of RCCC, and may be of reference value for the prognosis evaluation of RCCC.